Recent LTRN transcripts
Associated LTRN filings
| Panna Sharma | executive |
| David Margrave | executive |
| Kishor Bhatia | executive |
Good afternoon, and welcome to our third quarter 2024 earnings call.
As a reminder, this call is being recorded [Operator Instructions] A webcast replay of today's conference call will be available on our website at lanternpharma.com. Shortly after the call, we issued a press release after market close today summarizing our financial results and progress across the company for the third quarter ended September 30, 2024. A copy of this release is available through our website at lanternpharma.com where you will also find a link to the slides management will be referencing on today's call. We would like to remind everyone that remarks about future expectations, performance, estimates and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Lantern Pharma cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated. A number of factors could cause actual results to differ materially from those indicated by forward-looking statements, including results of clinical trials and the impact of competition.
Form that in actual be which the our report factors materially to found is concerning year our annual those the website. the from forward-looking on available on information file could XX, SEC results cause differ in ended with Additional December for and XXXX, on XX-K statements can
management. reflect intend replay Forward-looking on events by introductions to forward-looking and now off Lantern XXXX, today's start our strategy Panna, discussions today, Panna November statements made X, Pharma. Sharma, of occur Panna financial these achievements President of webcast, that highlight Lantern's by on circumstances we law. The be On and CEO, will conference and of efforts. I'd this call please does business from conference and overview our our Panna to not after call statements CEO with required available ahead. any webinar like Lantern will website. model to are and over of of as in of unless call of go update and Pharma Lantern have to Lantern's turn results and the today, recent and the things webcast an Pharma's followed Sharma operations, members R&D
spectrum. of our no is Good entire industry computational become longer and XXXX AI-guided pharmaceutical advancing across Lantern fundamental our clinical afternoon, are our Earnings drivers and results. joining development progress a they and The Quarter continued programs optional thank Pharma's have transformation. Call. in approaches drug the Third you for essential share Today, I'll experiencing financial tools, AI innovation discuss
drug life-changing XXXX, advance development. at execution, forefront traditional manufacturing in for cost RADR For and our of revolutionizing we AI a molecular transformation. has at the of trial XX patient been how has to drug our us clinical generate fraction design AI IPO the therapies. Lantern Since to is platform enabled of this to selection, develop programs
AI done, More importantly, trial actual progress LP-XXX. both our have companies ongoing trials, these we've ability X our and few Phase for HARMONIC something programs candidates to consistently AI-guided including demonstrated the and LP-XXX into other Phase patient very X
multiple This with early achievements efficiency. approach and quarter development for Fast These our is Track encouraging progress technology-first from data the cancer across validates maintaining AI-driven LP-XXX trial including capital in HARMONIC the recent significant our programs, while therapies clinical underscore approach FDA our accelerating of precision designation how glioblastoma.
a to patients' pipeline. oncology Our our while dedicated of teams mission and remain drives we're momentum and every is aspect our dramatically of cost our drug on commitment development, lives transform across cancer in the building that time laser-focused reducing the reflected work
yield transform Our company's the of leadership and as returns and should and and time drug patients learning precision in significant machine oncology costs of therapies data-first use AI and investors approach and for industry our the AI-centric matures innovative an to development. development lines adopts to
limited cancer put rate. detailed earnings last has cell which excited our clinical we The is our both We development, that Let who to many advancing me our in we benefit drug non-small patients, these are call. perspective, testing X Phase in a guided come our include we're X trial, oncology platform. HARMONIC in AI XX% with clinical of data have three options. precision evaluating updates alongside RADR these To AI-driven treatment and from our been trials, view candidates very Phase start never and ADC by saw all currently progress. on clinical candidates an through high-level our first In encouraging, smoker have several this particularly programs I'm of and X promising preclinical LP-XXX. have share ADC lung patients initial programs, These module. which clinical with
especially meaningful, a prior particularly are wide mutations. range signals since early kinase these of they cover So
expect We HARMONIC in Western all much already XX% a also enroll quarter. important Japan specifically continue this new XX expanding patients Taiwan, only medical lung XX%. This cancer into expansion begun about We're we've but and the each larger represents significant actually made not never [ where Japan countries, lung onboarding regions across about but accelerates see in portion LP-XXX of Asia, compared a which strides to U.S. these our our X/X countries, is cases also ] is positions in need enroll we've strategically to the expansion cancer establishing of in country, overall trial in across and trial to because total in is additional X smoker sites, our sites and we we high. sites enrollment patients the to cases, Taiwan. what particularly This of
importantly, in XX to we over lethal let Now toxicities any of enrolling clinical synthetic trials, both IA haven't the now profile advance and cohorts. of they We've highly these me and LP-XXX. positioning show as particularly turn candidates, Phase strong LP-XXX and first-in-human, clinically safety drug our encouraging patients centers in the And Both our programs. these any progress candidates. indications drug dosed dose potent and U.S. is we observed are to are programs This across limiting patient and across continue sharpen
molecule. for for GBM, demonstrates glioblastoma in us STAR-XXX this the of drive through designation developed our commercial unmet indications at potential cancer This news exciting in expedite FDA you significant owned GBM. and designation received Starlight LP-XXX, quarter opportunities many brain regarding not need know, granted or which and also The only provides to Therapeutics. development but will CNS wholly be also value We track subsidiary, our fast greater
clinical three and Therapeutics recurrent Phase At future for existing community patients been including two our Ia Johns we're we've trials, for they successfully from across Ib/II these patients The Hopkins enrolling GBM trials valuable GBM, LP-XXX Phase as sites, is Starlight trial academic site. in including inform of Indiana our one that centers, and in in in XXXX Starlight initiatives prestigious benefit GBM University Therapeutics. I'd Speaking program, gathering particularly time, cancer severely data the treatment development will Medicine same represents which will investigator-led opportunities, initiate as developments particularly we some potentially in Lantern highlight program. now significant to CNS expects a develop to like finance undertake. options This biomarker any further look and investors limited. exciting or forward we effective step our our are where to
has are crucial represents is was key can most first begun precise our also been biological validate trial. identify in as in As This will respond validate This many analysis in even in our initially through vivo expression LP-XXX significant of LP-XXX and now which better PTGRX our to using and drug drug. sensitivity likely platform's hypothesis We've platform predictive one response. validated monitoring insights, patients most biomarker trials. we know, of PTGRX response. Phase AI-driven data Ia you help will treatment RADR cohorts AI our AI clinical a CRISPR analyzing how discovery us identified This the demonstrating patient qPCR to that vitro that and perhaps mechanisms through to from predict also our allow X drive samples for experimentation. human it But in and to because look it can now at progress
[ for are priority FDA FDA We rare all designations designations to significant also new designations ATRT this carries The regulatory in approval. addition PRV These one voucher received ultra-rare in with very were each important new to receive This ]. three is LP-XXX. cancers. one childhood the pediatric recognition the a three quarter potential or particularly for existing review because upon
valued assets are be may companies with who not transferable excess they in million. those familiar that historically $XXX PRVs, to been pharmaceutical other have of For be sold can and
PRV biopharma them these unmet in valuable industry. We have our but amongst have of future has The and options to in often the options. its potential of impact but for four review future allows a valuable accelerate fact for or value these received these, potentially valuable not that holder limited where as is our patients, programs. of high future candidate no areas shareholders assets drug This are treatment children, need underscores each its also particularly designations only making highly LP-XXX FDA
scientific into has combination quarter and three particularly numerous how insights publications with about productive team future been and to trials. drug presentations our Our this significant guide
Dr. This growing AI-powered approach novel Officer, other for be these details important future development around areas will area highlighting and Kishor the ADC interest past provide will quarter, of work. oncology we RADR Scientific the our Chief paper an Our additional to published our that Bhatia, community. using peer-reviewed a platform in
models $X.X our past CFO the with today pharma to and more equivalents LP-XXX. major generated LP-XXX and our of and companies securities, Margrave, and new in in presented this also drug drug used at Hematologic conferences: Lantern insights synergy The role also AI-driven today, our the approximately level, the our financial top from insights, marketable synthetic million We development collaborators, cash, position At by These a and million Oncology, at candidate approach data of on closed with from $XX.X shared where get two about data. We'll anti-PD-X significant giving cash interest quarter immuno-oncology regarding summit, exciting drugs we Society David in my presentations help third we and findings operations. us new also colleague, details operations presented we quarter. where about strengthen approximately lethal
and I'm to talk our in more hand David operations. detail now to going finance to this over about So David?
third will $X.XX I quarter some for per XXXX financial September and third compared third XX, share recorded Panna, net of XXXX. quarter from of good approximately you, of loss or now the a ended approximately a per $X.X Thank share loss $X.XX for to highlights quarter the our XXXX. net million everyone. We share $X.X million of afternoon, or
$X.X This the largely for quarter the in was expenses million an third quarter approximately approximately XXXX, third increase R&D by of clinical our up trial million, activity. XXXX. $X.X of from driven For increase were
up for increases increase Our million general quarter from $X.X fees. third expenses third of The patent were legal approximately XXXX. of primarily attributable million in and increased to the professional and administrative slightly for approximately was the XXXX and quarter fees $X.X
and a our to product continue R&D margin expenses Our on G&A strong exceed our focus expenses our advancing reflecting by candidates pipeline.
third from the other was approximately other income by as from quarter of $XXX,XXX totaling a in loss offset quarter and interest net $XXX,XXX of offset the approximately and XXXX net XXXX. income operations compared third Our for interest of income income partially loss to
$XX.X at We XXXX. marketable million which late and position, provide XX, cash runway of this Our equivalents approximately was XXXX. cash anticipate cash as a us securities with balance September least will includes into
evolution we targeted ] financial continued will us believe of development the opportunities fuel of introduce additional solid and and RADR AI drug allow portfolio our oncology efficiently position [ and candidates of collaboration programs our to Importantly, continue targeted effectively. growth our and platform,
These shares. XX,XXX,XXX of with warrants and XXXX, stock purchase and September outstanding of XX.X million had stock, shares diluted options of us common XXXX. of purchase XX, we shares common shares to of outstanding outstanding, XX,XXX shares as September give XX, X,XXX,XXX shares combined outstanding outstanding options, a fully As our approximately to warrants total
Lantern to under observations model. our portfolio advancing and at presented. slide have RADR approximately drug be We our Many of primarily focused Our help very clinic, and development team into now X forth continues brought leading operating a can productive efforts. FTE the initial that's made research being are consultants currently of XX on employees and with in as you being hybrid the the see
of many trials. into drug efficient and candidates know, the development guided rapid AI-guided you three has of As clinical ongoing RADR
efficient these trials trials expect to internal lowering capital, our patients, while of dependency external we As and these use providers. and continue on across higher-cost making operations mature clinical to leverage functions, clinical capabilities enroll our
and on having and and decrease believe control our will overall gives ownership, trials. we in financial reduces company access our costs. to relating also activity only This, not the believe, our we to ownership, sites external strengthen hospitals to more allow capitalize us day-to-day but internal current team and our centers cancer Additionally, and information, direct greater expenditures, our observations
fortunate Panna turn developed the in across maturation and candidates, values both and trials the dedicated, highly LP-XXX, now focus our to back operations around efficient are in-human and clinical with We of motivated to to and the team our for have and Panna? on and Starlight call its Asia these core management a help alignment an clinical in LP-XXX cancers. update on drug first U.S. brain LP-XXX. I'll CNS us
David. Thanks,
Therapeutics. wild ] potentially trials, continue and subsidiary, brain been GBM also cancers. also [ Phase our and the to indications developed of LP-XXX launch largely II progress result and use and discussions started brain company of Starlight we as initiating significant approaches AI. has especially methods a for a the [ upcoming IDH of make data Ib uncover -- and the on for Phase and settings. CNS and is The optimize clinical use big CNS We ] drug site Notably, in like type the to cancer-focused that have stage for This recurrent in of the in are gliomas selection the hydrate computational
in If how and take on brain Chamberlain definitely CNS a our the both reviewed pediatric not the validate we to emphasize Mark and developments expect I significant the recent listen focus would They like webinar advance in you about further have Wednesdays Dr. Starlight, to webinars. webinar urge provide this to provide adult from moment and all insights our timing cancers. I'd to two that regarding cancer program. also of to details you trials
GBM nature milestone. need. designation Fast FDA's a is First, because particularly the This significant LP-XXX glioblastoma unmet medical of represents serious recognizes the for Track crucial meaningful it the designation and both in
in effective including We interactions line more and new formation of a of XX brings Advisory criteria of NDA the in make review. shave have Track Fast priority the more could several which accelerated approval our provides These FDA, biopharma Therapeutics review benefits lead nearly GBM partner. Equally important the hands our GBM the valuable advantages, a with in and met, years the frequent future most years. could potential to Scientific significantly larger asset in for for if rolling exciting status minds and development Board, respected some us approved therapy the together off single-agent time neuro-oncology. potentially of Starlight are is
our Dr. encouraged brain John work cancer and also Dr. has think us co-leads least us. their regimen neurological distinguished expertise she for Dr. establish Hopkins, that efforts combination in has injury but Sloan surgery; program their Dr. recognized been with Kimmel brain is supporter Society will center Board, both discuss Neurosurgery My colleague, cancer ] our Johns about at our clinical in NCI-funded operations serves internationally be devastating center who the experience from board Kishor help Hopkins and for Berger they -- our for internationally during of to Physician those DeAngelis, in in recipients malignancy. Kettering's repair. years the their and Lifetime Laterra brand brain co-directs me joined Let willingness helped where our Bhatia these approach tumor advisory oversees of help from an see She's brain Chief across the Center, in setting. unprecedented indication and the Dr. early tumor two in an directs later to and Berger Sydney significant Johns who will and is [ programs. brings cancers. ideas the continues speaks consortia; definitely Starlight Stuart [ network and who Executive members who Lisa XX CNS not all to guide his Cancer tumor of potential Dr. pursue clinical as Department has least, Kettering on Center, and sites, their program have brain webinar. The of join to Advisory UCSF, and recognized Mitchel guide treating you from Grossman Sloan Brain research ] Dr. their Cancer today Laterra, who brings his Center; tumor chairs mechanisms mapping Award Memorial of for Their includes and which expertise share recognized brain over expert directing to cancer cancer this internationally Memorial we Achievement Neuro-Oncology's volumes lastly, and tumor
and now with X candidates, completed you walk for lethal now doses. of cohorts escalating LP-XXX basket synthetic the Phase we've trial our The LP-XXX. me LP-XXX with Ia drug through some Let progress
across actively we're like now approaching exciting in dose-limiting GBM tumor Based solid response and PTGRX DNA seen We and types have triple-negative, those have an including patients haven't toxicities. any We're pharmacokinetic analysis, enrolling that we're our multiple tumors deficiency. that on milestone. high cancer, damage on zeroed pancreatic
trial. year-end a year reach or Our anticipate cohort and test see January impact concentrations early in the we're with that trials us help to our of of or in in them The and late therapeutic a our us drug LP-XXX, patients to designing above in on should We're identify X LP-XXX, enrollment aspect approach our is we medicine precision select We for just We're correlations and of where the our also exemplifies samples, particularly assay development. approach. diagnostic using molecular by future first excited candidate, developing now data a initial advancing dosage currently expect but patients. be patients diagnostic the certain which to that patient could expected the about advancing ones I for Phase companion therapeutic combination upcoming either also correlation completing cohorts candidate to key the XXXX. I'm and threshold, cancers. These progress invaluable not drug respond during PCR-based developing levels validating a treatment, this our but development progress safety right this will helping using most quantitative treatment. in to clinical identify comprehensive tools that the PTGRX molecular have likely hopefully, a
we're we're the LP-XXX toxicities. equally in doses program, our targets Turning escalating seeing currently progress. again, And making fourth to Phase dose-limiting cohort, favorable in hematologic trial. profile Ia We're dosing exciting safety like LP-XXX, with our cancers, which no
of to we about significant or accelerate The patients $X Based in in particularly lymphomas expect put to $X.X U.S. mantle current hematology those opportunity eventually in Ib subtypes, LP-XXX, future blood standard alone. We're perspective, hybrid after an me the we which why through for orphan lymphoma aggressive trajectory, double expanding potency and cancer billion all could the in phases billion new area this the this just current excited to early targeting double-hit but trial NHL treatments. We're are focused like here of LP-XXX of patients have that and profiles, in Let enrollment -- in molecules. additional Europe this multiple that somewhere setting. our and cell oftentimes, To and types, in in about ] specifically U.S. signs about opportunity consistent for our by nanomolar market year. Europe strong is market will our of in designations sites, we to [ alone, in we highlight to we're relapse II and range cell received mutations. remarkable we're ATM on sister together, advance annually range now nearly process very XX,XXX a there no B-cell two end mantle Again, XX,XXX substantial the general safety ] the we lymphomas. Phase lethal is encouraging [ seeing exceeding patterns to Phase believe both and our validate mid-XXXX. the LP-XXX at address look both these activity When of later-stage synthetic cancers potential significant the where unmet biological approach, drug
exciting. are adoption. importantly, more our treatment with kinase LP-XXX, strengthen the [ FDA partners will helped We XX these is is of therapy, testament options HARMONIC important fail and rapid guidance strong frequent no this in very very they data fast encouraging. designations, with during do commercial to is drug kind and pediatric this more real And options. and secure data-driven patients This thing treatment value which our ] disease clinicians After orphan has trial, where in This are designations. very for us focused believe there aid interaction very So has With talks the and drug initiatives. there and limited our been designations one excitement development FDA today. is track designations, rare a also
early particularly So group, in these small though meaningful. a are signals,
of in and monitoring We candidate. selection mutations the varying should also biomarker-based low intermediate the we range with also diverse set we see with interesting drug as some [ a or to mutation a patients mature implications burden, of U.S. have for ] kinase tumor
XX% EGFR including expanding cancer We In these Japan, ever stated commitment We're needed also continue non-small percentage and importantly, located lung our Asia South working Center in of ] cell each a Dr. as East Dr. and National Taiwan, Asia, Korea, the to comprise a in opening Tainan in underscores ] cohort. our in Lee very Hospital in nearly Kong Taiwan. In to This early Japan and of East We've is the some of among [ overwhelming Cheng University in or HARMONIC already majority to our country. patients are trial to in new in Japan smokers. X sites cases and where Cancer Taiwan, seen close and ], [ KOLs countries. Tokyo targetable Japan percentage of smokers. the significant enroll across Asia, National X Taiwan, efficacy Asia the it's U.S. signs sites City the remarkable Goa expand top amongst mutations earlier. at [ now kinase and in into mutations an ever up XX and I've and the initial
now this in this where in begun or licensing partnering, of co-development Now we we've an regarding is geography. Asia, that this asset because important discussions important represents think opportunity
Now regimens updates Officer, promising have now to trials our shape LP-XXX. and overview combination and Kishor? the Chief Bhatia, a Kishor our shaped and very will RADR, meaningful. over of future that specifically but informed for Ones that to highly I'll be ill provide guided number will call speak turn who been R&D an of help clinical by Scientific
Thank you, Panna.
mind, in well the selection trial, has clinical experiences treatment further A actively agents we clinical from collective contribute R&D additional are in indications. in we if treatments expand consensus As based ] therapeutics With LP-XXX, as with little, toxicity which that of of optimal to emerged likely the are Phase successes [ LP-XXX. have oncology overlapping studying of data combine are been to enhance successful accrue be our general potential most than efficacy about any, monotherapy. and areas combination I define we has that the as this rather to pursuing MTD that of
addressed RADR our clinical past immediate needs. the translation and have year, these teams For
this also Anderson, industry LP-XXX that engaged with and rapidly, from collaborators Massachusetts, shown UNICEF expert about slide to the scientists and displayed. Texas And these these fulfilling in several are MD Hopkins going being three which I here protocol show data, studies. accelerated new to the mention analysis combinations Two but and won't LP-XXX ISPA RADR are by the can are combinations. including in [ emerging of both Johns that we of latter team. [indiscernible]. that I'm time clinical unique include ] development is I for Today, bench distinct have Towards talk studies, [ Boston, ] have from
and mutations tumors breaks. with been in requires but with both slide transcription It in pathways This beyond PARP pathway. double-strand BRCAX ] PARP [ demonstrated combination cells, pathways of synergizes homologous What need LP-XXX also with synthetic in inhibitor recombination the necrotide BRCA-mutated have And in mechanisms multiple includes look cancer been the tumor in significant sufficient of see, attention per regulation in in doses X from it are causes draw was, aspect LP-XXX such repair of coupled milligrams [ HRD either BRCAX X with such surprising beyond those tumors wiped your to that to and lower formation X/X this which of genes would tumors threatened to Olaparib in Massachusetts lethality refractoriness grows, supported of at tumors a tumors mutations all [ a repair that fold lethality The as it homologous that extends our potential independent classical deficient have including ] with expression repair. ], affecting inhibitors. UNICEF expected So exceeding BRCA-ness [ [indiscernible] synthetic biosite we evidence results cells in at you that in also combine has resistant those with this significant low mutated like to Such but now BRCAX. tumor-specific factors success with have can become tumors likely right bioactivation similar synergies LP-XXX greater compared shows also HRD, to seen resistant up for LP-XXX or suggested out is Olaparib XX than additional ends you the PARP engage resistant. alone of this PTGRX the of sensitive to that in therefore, is, advantage in the LP-XXX drivers [indiscernible], therefore, PARP Clearly [ now [indiscernible] the the a tumor kg. by When achieve involving both additional which has to that our BRCAX. I LP-XXX of of by that involved [indiscernible] particularly is a further inhibitors LP-XXX, depletion its ] LP-XXX, the for the and as is as you of LP-XXX. ] to [indiscernible] synergy. this tumors is who tumor of generated loses combination collaborators therefore, data doses on RPA which, less at by of inhibitors make when one if A can Boston, attention LP-XXX pathways.
which clinical test be LP-XXX particularly in and excited protocol We to such are Ib combination our only of potential have this why several developed trial inhibitors, have a understanding from are a reasons inhibitor that actively might inhibitors. associated factors with agent arm. There resistance PARP comes by factors. the an This next Phase resistant dispersed power exceptional identifies the slide be to to for power the combinatorial been
become combats actually look to of road LP-XXX to of loss much PARP [ LP-XXX inhibitors our factors effectively [indiscernible] conversion, has effective. resistant data these to tumor suggests sensitive complex X even that If specifically allows of makes the been in tumors LP-XXX. you that gene ], at presence
been means also to this when not what highly LP-XXX, LP-XXX the does Additional to PARP that inhibitors, affect inhibitors. exposure, using perimeter arrest to using but loss upon is indicative, the LP-XXX reducing terms for not synergy agnostic for combination only in insights practical is [indiscernible] sensitivity with PARP thereby resistance. resistance PARP prolonged of But [indiscernible] have feature [indiscernible] loss of impairs [indiscernible] level
that Panel LP-XXX there clinically, cures, the treatment. in various significant drug, should indications, electron spironolactone, important In of means of combination see in in models The X other in indications. spironolactone proposing show DNA partner fully to discovery clinic following sensitivity non-oncology is Not you even to the understand This you vivo of damage, combination correlate these is including What combining was surprising, albeit this protein the ERCCX LP-XXX combination. In need order with responses are sustained drug be has in most resulted an as this D LP-XXX that A, observations see the GBM extensive the time spiral and LP-XXX, [indiscernible] administered, a most fold. can recurrence where was hypertension lines repair molecule settings of the FDA-approved [indiscernible] and effects in and to degrade we the scientific excellent tumors conducted. shown the to it. glioblastoma combinatorial acne. the multiple were of this with collaborators only experience, drug that in in C. better where specifically window therefore, we justified studies as for to cell to The [ Panel result serendipitous drug combination to targets battery rationale spironolactone use X X spironolactone, the to with slide, lower can which X a preclinical clinical from box LP-XXX used increases that of that is this a ERCCX What reasoning a bioavailability ] is of reduction can specifically by in
as that this is ERCCX we orthotopic out studies. XXX KD of equivalent at xenograft glioblastoma spironolactone [ its hours in human carried both and X at lowest ] subcutaneous level demonstrate code dosed ]. administration after slide, milligrams [ So per we time several In
enthusiastic the immune ATRT are select we of the LP-XXX shift cancers. activity oncology studies is are therapy ATRT, which types, lack orphan pediatric Group. I particularly and for renal glioblastoma, Even in LP-XXX the combination clinical designation including checkpoint with enhances exploring, other combination of in cancer with of the disease the and groups, In poetic any of and in neuro-oncology active pediatric children's we will now pancreatic the approved including discussions rare addition and third combining several to tumor spironolactone are ATRT, to inhibitors.
cytogenic ] as an detect inhibitors. for of up tumors. cells combined with checkpoint Lin stress a wider LP-XXX in could therefore, LP-XXX of DNA of breaks defect immune who molecule MD extend a steady induced replication stress treatment. response immune have strand as be the that involvement Dr. previously Anderson, feature suggest previously [ accumulation pharmacologically would to ] observed responsing population. with well LP-XXX DNA has immune collaboration activating replication developed this test tumor at correlates inhibitors during the checkpoint We We've potential our [indiscernible] shown [ following the benefits patient of the This and, with
escalate replication We [ have ] LP-XXX that response levels, particularly might [indiscernible], TNBC replication induce stress treatment in stress and [indiscernible]. therefore,
a inhibitor, see when induced can checkpoint ] As slide, to by stress effect compared defect replication what of LP-XXX for in were you expected by [ to would the in cycle cell similar murine a LP-XXX in XX% [ be with doses. of of combination a the relative show XX% cells the at tested this defend detect XX% shown inhibition tumors compared results ] We from assessed LP-XXX equimolar of induction a to increase XX% model. in slide results a alone The LP-XXX combination with in anti-PD-X tumor synthetic combination. from in growth enhancement TNBC [indiscernible] of then evidence effects antibody the
are modulate outside RADR LP-XXX based reduces might clinical function. upon it actually well both various study to emerging pathway, it now steady we as Panna. the once and appeared tumors. that such of the of results, [indiscernible] our clinical is are demand that that investigators [indiscernible] share and pathways, we important, with as but the business as partners [indiscernible] Many molecules inhibitors and Additional with pure rationally you is to cell back the exciting is near in development TNBC towards repair particularly like cold are and pathway I'll other mention, designed some discussion in [indiscernible] T Uniquely, a CRISPR in hope to which that turn from now [indiscernible]. Based include microenvironment analysis LP-XXX indicate combinations. And combinatorial these also data future
much. you Thank very Sure.
in see, of we exciting have lot turning up phases pathway As so with but and excitement for limited many excitement of you been a be should our avenues We that When ] number drug given we're in the and already can know range of especially new open potential for that be of there these are now can that research and there and far in biopharma community, as a widen and same importantly, to you the to very of a LP-XXX drugs clinical of the PARPS these in lot with has our partnering there the potentially some combinations meaningful in cancer, PD-X, the like part [ of window clinical opportunity. expect the PD-X. also attention their the drug ] community, LP-XXX. part a the and of arsenal [ community development are extended use and anti-PD-X tumors also therapeutic next
now Let's a of a bit little about webinars Wednesday. Webinar exciting month. about a lot We've talk one had
the For of those are details. that these the on in have backdrop webinars not listened
the November a will year the last webinar know not not last held Our and for December, the it's time. December XX, but challenging of on be last we of Wednesday Wednesday Wednesday
the and pick to and Lantern's to of will algorithms discovery, and this availability the future we of access development, extensive XX performing algorithms on will comments, leaderboard. which molecular across around try BBB the initiative we blood-brain drug middle therapeutic artificial power of with a webinar capability intelligence analysis and have The to feature modalities focus the the platform right data potential barrier RADR. radar webinar on the stages across predict top coordinated X module, data. According proprietary proprietary So discuss leverages to in of features That also enrich therapeutic the are development of the models of AI and molecular evaluate plans commercial month. specifically commercialization the permeability, use at
was exciting. algorithms. very of our And that's So early that some
continue In actually have discrimination. and refined to some and fact, mature their future get of they matured in significantly
about So XX we're data one of who's models. on with to those been that working our December pretty scientists excited on talk
progress cancer cancer journey fight other their has of impacting to are As patients progress, in -- been companies. and XXXX development our decisions accelerated you insights where a year of progress know, and also actually the influencing
where fostered lives and a affordable patients the and collective setting dedication we affected options. our Our are the an exciting with treatment shift future, improving transformational company, of for towards trajectory on cancer us efforts have
done clinical on you As on operations but see, can execution, team Kishor hand constantly one and the meticulous our the by team with is being also wheel focused work his and of innovation.
year, and have During readouts share as pipeline to quarter will advance with and we the fourth several next our we milestones company. and our clinical investors into
and is by them, before, amazing to just is and their prepare the medicine industry. I'd materials, powered is collaborations large-scale, in in levels said age becoming now now a would it available highly said the massive that And wasn't dedication. ultimately data us data, a is poised term and cancer to much If right that very tech health and we of harness computing of thank capabilities like long for companies in value more to before. to are power, widely data, more handicap so and it beginning to these our the team AI biotech our at industry. helping probably arena, I've prepare being these have really provide storage, take we for this leaders calls, insight in will patients long-term call. available be Companies increasing to golden for for and more bio personally gather which well ever by think patients being moment are create than and investors for data As the massive massive quality care these biotech it biopharma are
with questions I'd any the clarifications. call to now like or open So to that,
to you'd one ways. in two a question, do you If like of ask can so
and Q&A You the question. the can line.Yes. can on raise your tool you type and tool hand question to or first unmute the directly will we ahead your answer using click speak I'll go
data and one, our question lot just planned regarding another place And the Asia to is, at expect asked data up know XX interim a for of once opened we additional gather patients. more actively. HARMONIC, HARMONIC we LP-XXX also goal sites see in our in is we first patients trial the XX trial? As we'll to XX which expansion will the the The the analysis, take Asia, and impact do from
clinical big the HARMONIC those of but around next the if So And terms will mid is guide of us in earlier, next regarding two year year, expecting when it. we're expect readout events of next we really trial. middle not that
announced is how know, Next collaboration last Any our question. on we very well. is Therapeutics, efforts? As RADR collaboration quarter going you which Oregon and growing updates with
to the month IP to able to some the several perhaps end during for will collaboration correlate for biomarker -- regards be the joint first we probably We framework for phase set next before response to indications expect where the of that some their finalize the PDI their of good drug and and that questions year in inhibitor. time answer signatures
looking at collaborations. We additional are
I As -- biopharma We're you know, had more we've ones emerging would now on ones and focused say, three important portfolio. very much mid-market diverse more with larger more companies. companies. biotech with
Q&A partnership panel. probably larger has for that over to in So Can matured early the coming interest trial. question last now the given to too never the quite companies X.X it's years. I'll partnership smoker to the bit is we next the our interest? Although speak to platform a take increasing any attention speak
you lung a cell East XX% some South in is, gotten many never Taiwan non-small in as this companies Japan Japan, major Asia, of primarily percent started. smokers have larger and cancer we're regions to expect again, are now. XX-plus account We basis, with the similar. that China from conversation in Obviously, can epidemiological discussions for in so Korea, But I of pharma mentioned, cases
So receiving focus prevalence early, but that's very given there. of the interest are and we the given the disease
like hint biomarker to correlating that burden. to is, I'd did at a obviously, thing other signature add tumor lower intermediate we The mutation
all to good we enrolled more patients companies going of turning very the could initial that high We've lower understand for important is those burden, very chasing support looking status tumor burden also whereas that tumor as after data point obviously had down with clinically. a this this are that data. mark patients. of And we're get burden. the mutation terms human interest Now in mutation and mutation We're
this and biotech the Advisory these Berger, Board, market for potentially indications, Next agent my their lives and important, personal site-activated alkylating preeminent field. very question interested each of Clinical the is ] Grossman and making and the to of the in adult guys Scientific getting scientific quite board the very about drug If think again, think is progress we and Therapeutics for we're to be cancer up among transform patients, pediatric enrolling opening sites, the we're thrilled that are Starlight to feeling, and DeAngelis, on the and brain potential Dr. [ speaks them in join the the is patients. In for we members. We're this most advisory is stronger. and fundamentally novel volumes. We're quarter. Laterra decisions both
how see independently, again, launched other of go, to best for had are I sometime advance both But to XXXX and and those lantern early events think in fiscal or infrastructure interest lot maintain existing financing, the find to for capitalize and in parallel. of and be the we and a private we unique Starlight. trials and should for financing in Starlight develop try be planned public so people try And to the of that in some Starlight use lot trials. discipline. we've route meantime, believe it We'll IB we'll lot a the the a own grow there'll its trials. trials II We can
in and and in various with And if functions. if we're a markets ] with can Phase I thank contact MTD platform, long next synergy, certain executing. and have progress with [ we'll a reduces importantly, is there's the modality clinical two slowly access certain ] in everyone. the as and our very And up hour, for so use lot our cohorts, portfolio want improve. our an And do is important, about So II partner our the Lantern collaborators as very we next try will Phase that trials population. Well Phase markets certain opportunities spinouts markets operationally, we internally the solid think we're cancers and AI balance prepared the aspects we've to planned importantly, think out, that expanding both call, what's is to an to do vary capital in it trial. Very David really into carefully work very into there's that, we into our to us the can now we bring the sites patients, we're events, believe pointed partner clinical of into investors brings gives we of pointed and of a But the The where continue David conscious. today, closer Ninja to do us of to sheet more we where as but portfolio out, our But be at world-class be a this operations with across could but external we a our XX step-by-step, probably and correlate LP-XXX be make which good far assets leverage trials. our new creates to we existing that got also LP-XXX, think one will to or And across and our through to well. work But a Again, about trials get us for assets spend. sense, watching our capabilities. Internally, our minutes And for continue of several of of should [ begun value go team opportunities to capital think operations is in our to we're our out focused. but in We call continue our very aimed long from with to clinical significant is a build lot team. data. against the makes we to with again, or will more lot in the time, Asia combination going very cost this and term. what meticulous but allows take to planned execution us at same overview something a that group We with Ib rapidly with plan Ia to future be expect functionality. coming we
very in the again, historically. on and are So we things the range I of maintaining rate think have burn right we're operationally that doing kind the focused same
to I'd express are my a to I that, really also together, their to realize our time everyone development. for scalable oncology want gratitude partners with for for their the stakeholders thank brighter, to more our to deep And in So like team, care trying And oncology for support. and light way today. we that our and future drug
era. us era discovery very for you that our of believe drug listening bringing a much new the joining team -- thank that forefront [ and to is at we to us for ] our So joining new
Thank you.
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.